Cryo-Cell International Inc (DE:ZCY)
FRANKFURT:ZCY
ZCY Stock Chart & Stats
€3.56
€0.00(0.00%)
At close: 4:00 PM EST
€3.56
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.32 - €4.60
Previous CloseN/A
Volume0.00
Average Volume (3M)50.00
Market Cap
€28.44M
Enterprise Value€30.58M
Total Cash (Recent Filing)€2.90M
Total Debt (Recent Filing)€2.40M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Jul 09, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding8,055,150
10 Day Avg. Volume150
30 Day Avg. Volume50
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.07
Revenue Forecast (FY)€25.67M
Bulls Say, Bears Say
Bulls Say
High Gross MarginMid-70% gross margins indicate durable unit economics for Cryo-Cell’s processing and storage services. Strong margins provide a persistent buffer against rising costs, allow reinvestment in service quality and marketing, and support path to profitability as revenue stabilizes or scales.
Positive Operating And Free Cash FlowConsistent positive operating cash flow and recent positive free cash flow show the business can generate internal liquidity from core operations. This enhances near-term financial flexibility, reduces immediate dependency on external financing, and supports execution of remediation or growth initiatives.
Recurring, Annuity-style Revenue ModelThe business model centers on upfront processing plus recurring storage fees, creating predictable, annuity-like revenue and customer lock-in. Durable recurring streams improve cash visibility, support unit economics, and increase lifetime customer value, aiding long-term planning and retention-focused investments.
Bears Say
Negative Stockholders' EquityA persistent stockholders’ deficit materially reduces financial flexibility and increases creditor and listing risk. Negative equity constrains capital-raising options, can force dilutive financings or asset sales to remediate, and undermines investor and counterparty confidence over the medium term.
Weak/declining Revenue TrendFlat to declining top-line growth limits the company’s ability to leverage strong gross margins into sustained profits. Without secular revenue improvement or higher enrollments, margin strength may not translate into durable operating gains, leaving profitability and equity remediation uncertain.
NYSE Listing & Remediation RiskWhile a compliance plan was accepted, the extended remediation period creates prolonged regulatory scrutiny and execution risk. Failure to meet targets could trigger delisting, compel urgent financing or restructuring, and distract management from long-term growth initiatives during the plan period.
Cryo-Cell International News
ZCY FAQ
What was Cryo-Cell International Inc’s price range in the past 12 months?
Cryo-Cell International Inc lowest stock price was €2.32 and its highest was €4.60 in the past 12 months.
What is Cryo-Cell International Inc’s market cap?
Cryo-Cell International Inc’s market cap is €28.44M.
When is Cryo-Cell International Inc’s upcoming earnings report date?
Cryo-Cell International Inc’s upcoming earnings report date is Jul 09, 2026 which is in 18 days.
How were Cryo-Cell International Inc’s earnings last quarter?
Cryo-Cell International Inc released its earnings results on Apr 14, 2026. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.017 by €0.026.
Is Cryo-Cell International Inc overvalued?
According to Wall Street analysts Cryo-Cell International Inc’s price is currently Overvalued.
Does Cryo-Cell International Inc pay dividends?
Cryo-Cell International Inc does not currently pay dividends.
What is Cryo-Cell International Inc’s EPS estimate?
Cryo-Cell International Inc’s EPS estimate is 0.
How many shares outstanding does Cryo-Cell International Inc have?
Cryo-Cell International Inc has 8,055,150 shares outstanding.
What happened to Cryo-Cell International Inc’s price movement after its last earnings report?
Cryo-Cell International Inc reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.017. Following the earnings report the stock price went up 2.128%.
Which hedge fund is a major shareholder of Cryo-Cell International Inc?
Currently, no hedge funds are holding shares in DE:ZCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryo-Cell International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.01%
12-Months-Change
Fundamentals
Return on Equity
15.82%
Trailing 12-Months
Asset Growth
-5.43%
Trailing 12-Months
Company Description
Cryo-Cell International Inc
Cryo-Cell International, Inc. specializes in the cryogenic preservation and processing of cells, primarily focusing on collecting and storing umbilical cord blood stem cells for personal family use. The company also offers a cord tissue banking service, securing a section of the umbilical cord itself. This tissue is a valuable source of mesenchymal stem cells, which are utilized in regenerative medicine to address a range of conditions, including various heart and kidney diseases, Amyotrophic Lateral Sclerosis (ALS), wound healing, and autoimmune disorders. Furthermore, Cryo-Cell manufactures and distributes its proprietary PrepaCyte CB processing system, specifically designed for umbilical cord blood stem cells. With a substantial global presence, the company safeguards approximately 500,000 units of cord blood and cord tissue stem cells. Their marketing efforts include direct outreach to expectant parents, alongside disseminating information through a network of healthcare professionals such as obstetricians, pediatricians, childbirth educators, and certified nurse-midwives. Established in 1989, Cryo-Cell International, Inc. is headquartered in Oldsmar, Florida.
ZCY Stock 12 Month Forecast
Average Price Target
―Technical Analysis
American Shared Hospital Services
―
Concord Medical Services
―
―
DocGo
―
P3 Health Partners
―
Options Prices
Currently, No data available
---